|
US2018117126A1
|
|
Treatment of inflammatory illnesses with ace2
|
|
CN107889487A
|
|
For treating the bicyclic tetrahydro sulphur azepine * derivatives of tumour and/or infectious diseases
|
|
US2016304620A1
|
|
Preparations and methods for treating a GD2 positive cancer
|
|
EP3620173A1
|
|
Preparations and methods for treating a gd2 positive cancer
|
|
AU2014215996A1
|
|
Treatment of fibroses and liver disorders
|
|
CN105263512A
|
|
Modified ace2 polypeptides
|
|
CA2834000A1
|
|
Method for treating a gd2 positive cancer
|
|
EP2875827A1
|
|
Preparations and methods for treating a GD2 positive cancer
|
|
EP2861251A1
|
|
Method for treating a gd2 positive cancer
|
|
WO2013189516A1
|
|
Method for treating a gd2 positive cancer
|
|
EP2601965A1
|
|
Compositions for preventing or treating adverse reactions of EGFR inhibition
|
|
EP2471548A1
|
|
siRNA against Cbl-b and optionally IL2 and IL12 for use in the treatment of cancer
|
